AlloSite Tx
  • Home
  • About Us
    • Our Mission
    • Our Team
  • Science
    • Pipeline
    • Platform
    • Publications
  • News
  • Contact Us
Select Page

Acquisition of clinical stage integrin activator program from Gossamer Bio

by 149bio | Feb 23, 2023 | Press Release

Clinical asset planned to be advanced in Lupus Nephritis and other indications Program includes first-in-class integrin activator for myeloid cell integrin CD11b CD11b activation reduces myeloid overactivation and tissue damage Target validated in multiple auto-immune...

Recent Posts

  • Allosite Therapeutics to Present Four Posters at American Society of Nephrology Kidney Week 2025
  • AlloSite Therapeutics launches
  • Acquisition of clinical stage integrin activator program from Gossamer Bio
  • Nomination of integrin α3β1 as a target for its unique agonist antibodies as therapeutics for kidney disease

Recent Comments

    Archives

    • October 2025
    • August 2023
    • February 2023
    • October 2022

    Categories

    • Announcement
    • Press Release

    Meta

    • Log in
    • Entries feed
    • Comments feed
    • WordPress.org